Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1953 1
1955 1
1956 2
1958 2
1959 1
1964 1
1965 10
1966 15
1967 28
1968 35
1969 49
1970 58
1971 57
1972 56
1973 73
1974 62
1975 79
1976 78
1977 68
1978 68
1979 76
1980 100
1981 100
1982 123
1983 184
1984 174
1985 179
1986 146
1987 166
1988 178
1989 170
1990 188
1991 198
1992 221
1993 166
1994 183
1995 208
1996 195
1997 191
1998 182
1999 202
2000 209
2001 191
2002 185
2003 189
2004 182
2005 227
2006 220
2007 190
2008 186
2009 221
2010 245
2011 224
2012 241
2013 250
2014 235
2015 275
2016 252
2017 267
2018 253
2019 236
2020 271
2021 292
2022 254
2023 235
2024 124

Text availability

Article attribute

Article type

Publication date

Search Results

9,256 results

Results by year

Filters applied: . Clear all
Page 1
Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.
Stern A, Green H, Paul M, Vidal L, Leibovici L. Stern A, et al. Cochrane Database Syst Rev. 2014 Oct 1;2014(10):CD005590. doi: 10.1002/14651858.CD005590.pub3. Cochrane Database Syst Rev. 2014. PMID: 25269391 Free PMC article. Review.
DATA COLLECTION AND ANALYSIS: Two review authors independently assessed risk of bias in each trial and extracted data from the included trials. We contacted authors of the included trials to obtain missing data. ...Risk ratios (RR) with 95% confidence intervals (CI) were e …
DATA COLLECTION AND ANALYSIS: Two review authors independently assessed risk of bias in each trial and extracted data from the includ …
Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
Barnes H, Holland AE, Westall GP, Goh NS, Glaspole IN. Barnes H, et al. Cochrane Database Syst Rev. 2018 Jan 3;1(1):CD010908. doi: 10.1002/14651858.CD010908.pub2. Cochrane Database Syst Rev. 2018. PMID: 29297205 Free PMC article. Review.
SEARCH METHODS: We performed searches on CENTRAL, MEDLINE, Embase, CINAHL, and Web of Science up to May 2017. We handsearched review articles, clinical trial registries, and reference lists of retrieved articles. ...Clinical practice guidelines should advise …
SEARCH METHODS: We performed searches on CENTRAL, MEDLINE, Embase, CINAHL, and Web of Science up to May 2017. We handsearched review article …
Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer.
Burness CB, Duggan ST. Burness CB, et al. Drugs. 2016 Sep;76(14):1393-402. doi: 10.1007/s40265-016-0633-9. Drugs. 2016. PMID: 27568360 Review.
The approved regimen of oral twice-daily trifluridine/tipiracil (35 mg/m(2) twice daily on days 1-5 and 8-12 of each 28-day cycle) significantly improved overall survival and progression-free survival and was associated with a significantly higher disease control rate than placeb …
The approved regimen of oral twice-daily trifluridine/tipiracil (35 mg/m(2) twice daily on days 1-5 and 8-12 of each 28-day cycle) significa …
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours.
Leary A, Oaknin A, Trigo JM, Moreno V, Delord JP, Boni V, Braña I, Fernández C, Kahatt C, Nieto A, Cullell-Young M, Zeaiter A, Subbiah V. Leary A, et al. Eur J Cancer. 2023 Oct;192:113259. doi: 10.1016/j.ejca.2023.113259. Epub 2023 Jul 28. Eur J Cancer. 2023. PMID: 37634282 Free article.
Safety profile at approved dose (3.2 mg/m(2) every 3 weeks) was acceptable and manageable in 105 adult SCLC patients from a phase II basket trial. This study analyses safety data from several solid tumours treated at the lurbinectedin-approved dose. METHODS: Data were pool …
Safety profile at approved dose (3.2 mg/m(2) every 3 weeks) was acceptable and manageable in 105 adult SCLC patients from a phase II basket …
Hematological adverse events in the management of glioblastoma.
Garcia CR, Myint ZW, Jayswal R, Wang C, Morgan RM, Butts AR, Weiss HL, Villano JL. Garcia CR, et al. J Neurooncol. 2022 Jan;156(1):153-161. doi: 10.1007/s11060-021-03891-8. Epub 2021 Nov 24. J Neurooncol. 2022. PMID: 34820776 Free PMC article.
BACKGROUND: Hematological adverse events (HAEs) are common during treatment for glioblastoma (GBM), usually associated with temozolomide (TMZ). Their clinical value is uncertain, as few investigations have focused on outcomes for HAEs during GBM treatment. METHODS: We comb …
BACKGROUND: Hematological adverse events (HAEs) are common during treatment for glioblastoma (GBM), usually associated with temozolomide (TM …
Dimethyl fumarate for multiple sclerosis.
Xu Z, Zhang F, Sun F, Gu K, Dong S, He D. Xu Z, et al. Cochrane Database Syst Rev. 2015 Apr 22;2015(4):CD011076. doi: 10.1002/14651858.CD011076.pub2. Cochrane Database Syst Rev. 2015. PMID: 25900414 Free PMC article. Review.
We also communicated with investigators participating in trials of dimethyl fumarate and the Biogen Idec Medical Information. SELECTION CRITERIA: We included randomised, controlled, parallel-group clinical trials (RCTs) with a length of follow-up equal to or greater …
We also communicated with investigators participating in trials of dimethyl fumarate and the Biogen Idec Medical Information. SELECTION CRIT …
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
Prefontaine E, Macdonald JK, Sutherland LR. Prefontaine E, et al. Cochrane Database Syst Rev. 2010 Jun 16;(6):CD000545. doi: 10.1002/14651858.CD000545.pub3. Cochrane Database Syst Rev. 2010. PMID: 20556747 Updated. Review.
BACKGROUND: The results from controlled clinical trials investigating the efficacy of azathioprine and 6-mercaptopurine for the treatment of active Crohn's disease were conflicting and controversial. ...A steroid sparing effect was seen with an OR of 3.69 (95% CI 2.12 - 6. …
BACKGROUND: The results from controlled clinical trials investigating the efficacy of azathioprine and 6-mercaptopurine for the treat …
Tamoxifen vs. non-tamoxifen treatment for advanced melanoma: a meta-analysis.
Beguerie JR, Xingzhong J, Valdez RP. Beguerie JR, et al. Int J Dermatol. 2010 Oct;49(10):1194-202. doi: 10.1111/j.1365-4632.2010.04529.x. Int J Dermatol. 2010. PMID: 20883410 Review.
MEDLINE, The Cochrane Database of Systemic Reviews, The Cochrane Central Register of Controlled Trials, EMBASE and LILACS were searched for randomized controlled trials comparing chemotherapy using and not using TAM in any dose, in patients of any age with advanced melanom …
MEDLINE, The Cochrane Database of Systemic Reviews, The Cochrane Central Register of Controlled Trials, EMBASE and LILACS were searched for …
Systematic review of piperacillin-induced neutropenia.
Scheetz MH, McKoy JM, Parada JP, Djulbegovic B, Raisch DW, Yarnold PR, Zagory J, Trifilio S, Jakiche R, Palella F, Kahn A, Chandler K, Bennett CL. Scheetz MH, et al. Drug Saf. 2007;30(4):295-306. doi: 10.2165/00002018-200730040-00002. Drug Saf. 2007. PMID: 17408306 Review.
Causality assessments were performed. Six published case reports, three cohort studies, 178 clinical trials and two compilations of phase I-III trials were reviewed. Review of case reports was notable in that the duration of beta-lactam therapy prior to the noting of le …
Causality assessments were performed. Six published case reports, three cohort studies, 178 clinical trials and two compilations of p …
Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma.
Mathew Thomas V, Tripathi N, Agarwal N, Swami U. Mathew Thomas V, et al. Expert Rev Anticancer Ther. 2022 Apr;22(4):335-341. doi: 10.1080/14737140.2022.2049763. Epub 2022 Mar 10. Expert Rev Anticancer Ther. 2022. PMID: 35249433 Review.
AREAS COVERED: We review the available data on SG, including mechanism of action, pharmacology, efficacy, safety, and clinical studies regarding locally advanced or metastatic urothelial cancer. EXPERT OPINION: SG performed well in the TROPHY-U-01 phase II trial wit …
AREAS COVERED: We review the available data on SG, including mechanism of action, pharmacology, efficacy, safety, and clinical studie …
9,256 results